

Del Mar Pharmaceuticals to present at BioContact Québec

Vancouver, BC, October 5, 2010 – Del Mar Pharmaceuticals announced today that Jeffrey Bacha, President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, October 6, 2010, at 2:30 p.m., at BioContact Québec. The event is being held at the Château Frontenac Hotel in Quebec City. BioContact Québec is a biopharmaceutical partnership symposium attended by over 800 participants.

About Del Mar Pharma

Del Mar Pharmaceuticals is focused on the development and commercialization of proven cancer therapies in high-impact orphan drug indications. The Company's lead product, VAL-083, benefits from an extensive clinical and pre-clinical research history via studies sponsored by the National Cancer Institute in the United States. Previously published clinical data demonstrate efficacy of chemotherapy with VAL-083 in the treatment GBM and other tumor types.